PE20140134A1 - Metodos para mejorar la oxigenacion del tejido en peligro - Google Patents

Metodos para mejorar la oxigenacion del tejido en peligro

Info

Publication number
PE20140134A1
PE20140134A1 PE2013001082A PE2013001082A PE20140134A1 PE 20140134 A1 PE20140134 A1 PE 20140134A1 PE 2013001082 A PE2013001082 A PE 2013001082A PE 2013001082 A PE2013001082 A PE 2013001082A PE 20140134 A1 PE20140134 A1 PE 20140134A1
Authority
PE
Peru
Prior art keywords
c2ho4
c2ho
blood
patient
methods
Prior art date
Application number
PE2013001082A
Other languages
English (en)
Inventor
Martin Emanuele
Original Assignee
Mast Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mast Therapeutics Inc filed Critical Mast Therapeutics Inc
Publication of PE20140134A1 publication Critical patent/PE20140134A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN METODO PARA AUMENTAR LA SEGURIDAD Y LA EFICACIA DE LAS TRANSFUSIONES DE SANGRE QUE COMPRENDE ADMINISTRAR A UN PACIENTE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COPOLIMERO DE POLIOXIETILENO/ POLIOXIPROPILENO CUYA FORMULA ES HO(C2H4O)a-(C3H6O)b-(C2H4O)aH, DONDE b ES UN NUMERO ENTERO TAL QUE LA PORCION HIDROFOBA (C3H6O) TIENE UN PESO MOLECULAR DE 950 A 4000 DALTONES, Y a ES UN NUMERO ENTERO TAL QUE LA PORCION HIDROFILA (C2H4O) REPRESENTA DEL 50 AL 90% EN PESO DEL COMPUESTO; EN DONDE DICHA COMPOSICION SE ADMINISTRA AL PACIENTE ANTES, CONCOMITANTE CON O DESPUES DE LA TRANSFUSION DE SANGRE. TAMBIEN SE REFIERE A UN METODO PARA REDUCIR LOS EFECTOS ADVERSOS DE LA TRANSFUSION DE UN PACIENTE CON SANGRE COMPROMETIDA POR LA LESION DE ALMACENAMIENTO
PE2013001082A 2010-11-15 2011-11-15 Metodos para mejorar la oxigenacion del tejido en peligro PE20140134A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41351910P 2010-11-15 2010-11-15

Publications (1)

Publication Number Publication Date
PE20140134A1 true PE20140134A1 (es) 2014-02-14

Family

ID=46084364

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001082A PE20140134A1 (es) 2010-11-15 2011-11-15 Metodos para mejorar la oxigenacion del tejido en peligro

Country Status (17)

Country Link
US (2) US20130177524A1 (es)
EP (1) EP2640684A4 (es)
JP (2) JP5823530B2 (es)
KR (2) KR20130097795A (es)
CN (1) CN103328427A (es)
AU (1) AU2011329088B2 (es)
BR (1) BR112013011858A2 (es)
CA (1) CA2817542A1 (es)
CL (1) CL2013001382A1 (es)
EA (1) EA201390720A1 (es)
IL (1) IL226285A0 (es)
MX (1) MX2013005457A (es)
NZ (1) NZ610441A (es)
PE (1) PE20140134A1 (es)
SG (1) SG190695A1 (es)
WO (1) WO2012068079A1 (es)
ZA (1) ZA201303416B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013011858A2 (pt) * 2010-11-15 2017-03-21 Mast Therapeutics Inc métodos para reforçar oxigenação de tecido comprometido
GB201207543D0 (en) * 2012-05-01 2012-06-13 Haemair Ltd Treatment of transfusion blood
US20160235781A1 (en) * 2013-10-16 2016-08-18 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
EP3166617B1 (en) 2014-07-07 2024-01-10 LifeRaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
EP3873441A4 (en) * 2018-12-10 2022-06-29 Arshintseva, Elena Valentinovna A new use of the poloxamer as a pharmacologically active substance
CN118076227A (zh) * 2021-08-18 2024-05-24 欧姆尼奥克斯股份有限公司 用于器官保存的h-nox蛋白

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071649A (en) 1986-05-15 1991-12-10 Emory University Method of preventing blockage in catheters
US5032394A (en) 1986-05-15 1991-07-16 Emory University Method of treating burns
US5017370A (en) 1986-05-15 1991-05-21 Emory University Improved method of performing angioplasty procedures
US4873083A (en) 1986-05-15 1989-10-10 Emory University Fibrinolytic composition
US5078995A (en) 1986-05-15 1992-01-07 Emory University Fibrionolytic composition
US4937070A (en) 1986-05-15 1990-06-26 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5089260A (en) 1986-05-15 1992-02-18 Emory University Method of treating ischemic tissue
US4837014A (en) 1986-05-15 1989-06-06 Emory University An improved method of treating sickle cell anemia
US5047236A (en) 1986-05-15 1991-09-10 Emory University Method of treating stroke
US4897263A (en) * 1986-05-15 1990-01-30 Emory University Methods and compositions for treatment of pathological hydrophobic interactions in biological fluids
US5039520A (en) 1986-05-15 1991-08-13 Emory University Plasma extender
US5028599A (en) 1986-05-15 1991-07-02 Emory University Method of treating mycardial damage
US5041288A (en) 1986-05-15 1991-08-20 Emory University Method of treating tissue damaged by reperfusion injury
US5064643A (en) 1986-05-15 1991-11-12 Emory University Method for treating sickle cell disease
US5030448A (en) 1986-05-15 1991-07-09 Emory University Method of delivering drugs to damaged or diseased tissue
US4801452A (en) 1986-05-15 1989-01-31 Hunter Robert L Fibrinolytic composition
US5080894A (en) 1986-05-15 1992-01-14 Emory University Method and composition for reducing tissue damage
US4997644A (en) 1986-05-15 1991-03-05 Emory University Method of treating adult respiratory distress syndrome
US4879109A (en) 1986-05-15 1989-11-07 Emory University Method for treating burns
US5696298A (en) 1991-03-19 1997-12-09 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
HUT67762A (en) * 1991-03-19 1995-04-28 Cytrx Corp Polyoxypropylene/polyoxiethylene copolymers with improved biological activity and process for producing thereof
US5605687A (en) 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US7087369B2 (en) * 2003-12-17 2006-08-08 The Regents Of The University Of California Cornea preservation medium
US20070237740A1 (en) * 2004-09-27 2007-10-11 Vical, Inc. Formulations and Methods for Treatment of Inflammatory Diseases
AU2008287419A1 (en) * 2007-08-10 2009-02-19 Synthrx, Inc. Polymer therapy for the treatment of chronic microvascular diseases
BR112013011858A2 (pt) * 2010-11-15 2017-03-21 Mast Therapeutics Inc métodos para reforçar oxigenação de tecido comprometido

Also Published As

Publication number Publication date
AU2011329088B2 (en) 2016-02-25
EA201390720A1 (ru) 2013-10-30
ZA201303416B (en) 2017-03-29
WO2012068079A1 (en) 2012-05-24
CL2013001382A1 (es) 2013-12-20
US20150093368A1 (en) 2015-04-02
BR112013011858A2 (pt) 2017-03-21
SG190695A1 (en) 2013-07-31
JP5823530B2 (ja) 2015-11-25
NZ610441A (en) 2016-02-26
JP2016041714A (ja) 2016-03-31
KR20130097795A (ko) 2013-09-03
JP2014506234A (ja) 2014-03-13
US20130177524A1 (en) 2013-07-11
CN103328427A (zh) 2013-09-25
EP2640684A1 (en) 2013-09-25
EP2640684A4 (en) 2014-04-30
IL226285A0 (en) 2013-07-31
MX2013005457A (es) 2013-10-17
CA2817542A1 (en) 2012-05-24
AU2011329088A1 (en) 2013-06-27
KR20150124457A (ko) 2015-11-05

Similar Documents

Publication Publication Date Title
PE20140134A1 (es) Metodos para mejorar la oxigenacion del tejido en peligro
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
RU2013121788A (ru) Ингибиторы репликации вич
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
BR112018014027A2 (pt) composições e métodos para administração intravenosa de 2-bromo-1-(3,3-dinitroazeditin-1-il)etanona
AR068816A1 (es) Composiciones de brimonidina mejorada para el tratamiento del eritema
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201591027A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112015011179A2 (pt) composições aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
BR112013013950A2 (pt) antagonista de lpa1 policíclico e usos dos mesmos
CR20140086A (es) Tratamientos de combinación para hepatitis c
EA201500293A1 (ru) Антихолинэргическая нейропротективная композиция и способы
BR112015021470A2 (pt) conjugado de polímero para administração de um agente bioativo
RU2018123666A (ru) Способ лечения рака у млекопитающего, включая человека, с примененим деплеции метионина и аспарагина
PE20150226A1 (es) Agentes terapeuticos para administracion subcutanea optimizados
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
RU2016151973A (ru) Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами
AR091977A1 (es) El uso de antitrombina en la oxigenacion de membranas extracorporeas
CO6771403A2 (es) Derivado de acilbenceno
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii
BR112015024897A2 (pt) derivado de fenila
SV2013004582A (es) Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias

Legal Events

Date Code Title Description
FA Abandonment or withdrawal